Loading...
Treatment for stage II colorectal cancer (CRC) after primary surgical management remains controversial. Adjuvant chemotherapy for patients who have stage II CRC without high-risk features results in limited survival improvement, and adding oxaliplatin to 5-fluorouracil (5-FU) provides no additional benefit (J Clin Oncol 2009; 27:3109). Thus, many advocate adjuvant treatment only for high-risk stage II disease. The presence of microsatellite instability (MSI) in stage II tumors arising from defective DNA mismatch repair (dMMR) correlates with a favorable prognosis after surgery alone, and some studies indicate a potential detriment if patients with MSI and stage II CRC are treated with adjuvant 5-FU.
Now, investigators have evaluated a batter…